Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

[1]  D. Fruci,et al.  Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors , 2020, Frontiers in Immunology.

[2]  R. Miceli,et al.  Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. , 2019, The oncologist.

[3]  H. Lee,et al.  Tumor immune response and immunotherapy in gastric cancer , 2019, Journal of pathology and translational medicine.

[4]  E. Van Cutsem,et al.  Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Kazuhiro Yoshida,et al.  Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial , 2018, The Lancet.

[6]  V. Canzonieri,et al.  Immunotherapy for Gastric Cancer: Time for a Personalized Approach? , 2018, International journal of molecular sciences.

[7]  P. Philip,et al.  Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial , 2018, JAMA oncology.

[8]  A. Barzi,et al.  Outlooks on Epstein-Barr virus associated gastric cancer. , 2018, Cancer treatment reviews.

[9]  J. Ji,et al.  Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients , 2018, Oncoimmunology.

[10]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[11]  C. Figdor,et al.  Migrating into the Tumor: a Roadmap for T Cells. , 2017, Trends in cancer.

[12]  J. Rodríguez.  HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation , 2017, Oncology letters.

[13]  H. Bae,et al.  Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology , 2017, World journal of gastrointestinal oncology.

[14]  E. Oki,et al.  Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells. , 2017, Gastroenterology.

[15]  M. Ducreux,et al.  Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. , 2017, European journal of cancer.

[16]  P. Ascierto,et al.  Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. , 2017 .

[17]  D. Gabrilovich.  Myeloid-Derived Suppressor Cells , 2017, Cancer Immunology Research.

[18]  D. Lin,et al.  PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. , 2016, Human pathology.

[19]  J. Zhang,et al.  Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance , 2016, Oncotarget.

[20]  P. Hegde,et al.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.

[21]  Anne Berger,et al.  Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. , 2015, World journal of gastroenterology.

[22]  C. Borg,et al.  FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA). , 2015 .

[23]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[24]  E. Tartour,et al.  VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors , 2015, The Journal of experimental medicine.

[25]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[26]  S. Natsugoe,et al.  Decreased density of CD3+ tumor‐infiltrating lymphocytes during gastric cancer progression , 2014, Journal of gastroenterology and hepatology.

[27]  Mithat Gonen,et al.  Stage-Stratified Prognosis of Signet Ring Cell Histology in Patients Undergoing Curative Resection for Gastric Adenocarcinoma , 2014, Annals of Surgical Oncology.

[28]  E. Tartour,et al.  VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. , 2013, Cancer research.

[29]  A. Davey,et al.  Prognostic significance of signet ring gastric cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Novo,et al.  CORRELAÇÃO DA INFILTRAÇÃO DAS CÉLULAS NATURAL KILLER (NK) CD 57+ NO PROGNÓSTICO DO ADENOCARCINOMA GASTRICO Gástrico correlation of natural killer cell with the prognosis of gastric adenocarcinoma , 2012 .

[31]  H. Pircher,et al.  E-cadherin promotes accumulation of a unique memory CD8 T-cell population in murine salivary glands , 2011, Proceedings of the National Academy of Sciences.

[32]  E. Tartour,et al.  Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy , 2011, Cancer and Metastasis Reviews.

[33]  M. Teh,et al.  HLA‐DR antigen expression in intestinal‐type and diffuse‐type gastric carcinoma , 2010, Cancer.

[34]  M. Gulubova,et al.  Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[35]  P. Guilford,et al.  E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. , 2009, Cancer research.

[36]  S. Chae,et al.  Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer , 2008, British Journal of Cancer.

[37]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[38]  E. Bloemena,et al.  Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients , 2006, Cancer Immunology, Immunotherapy.

[39]  Hong Nguyen,et al.  Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. , 2004, Archives of pathology & laboratory medicine.

[40]  S. Natsugoe,et al.  Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. , 2000, Cancer letters.

[41]  S. Natsugoe,et al.  Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.

[42]  L. Ellis,et al.  Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  H. Zola,et al.  Isolation of Whole Mononuclear Cells from Peripheral Blood and Cord Blood , 1996, Current protocols in immunology.

[44]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[45]  R. Scolyer,et al.  Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.

[46]  H. Ohtani,et al.  Differing microvasculature in the two major types of gastric carcinoma: a conventional, ultrastructural and ultrastructural immunolocalization study of von Willebrand factor , 2005, Virchows Archiv A.